5 Best Longevity and Anti-Aging Stocks to Buy

3. Eli Lilly and Company (NYSE:LLY)

Short Percentage of Shares Outstanding: 1.10%

On June 16, Austin-based neuroscience company 4E Therapeutics announced that it had been acquired by Eli Lilly and Company (NYSE:LLY). 4E Therapeutics is developing a pipeline of orally available MNK inhibitors designed to treat chronic pain by targeting the MNK-eIF4E signaling pathway in peripheral sensory neurons. Financial terms of the transaction were not disclosed.

On the same day, Eli Lilly and Company (NYSE:LLY) reported new Phase 1 data from the AJX-101 study showing that its investigational type II JAK2 inhibitor demonstrated a favorable safety profile and encouraging clinical activity in patients with myelofibrosis who had previously failed treatment with a type I JAK2 inhibitor. The therapy was specifically designed to selectively target the type II conformation of the JAK2 kinase, potentially offering a differentiated treatment option for patients who develop resistance to currently available therapies. Lilly recently added the program to its development pipeline through an acquisition, further expanding its oncology portfolio.

Founded in 1876 and headquartered in Indianapolis, Indiana, Eli Lilly and Company (NYSE:LLY) is a global pharmaceutical leader focused on developing innovative medicines for diabetes, obesity, cancer, immunology, and neuroscience. The company has emerged as one of the key players in the longevity and healthy-aging space through its groundbreaking metabolic disease treatments, while continuing to invest heavily in next-generation therapies across multiple high-growth areas of healthcare.